Events | 2017.06.22
FDA approves first subcutaneous C1 Esterase Inhibitor to treat rare genetic disease
SILVER SPRING, Md., June 22, 2017 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Haegarda, the first C1 Esterase Inhibitor (Human) for subcutaneous (under the skin) administration to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult...
For more information, please visit
http://www.prnewswire.com/news-releases/[...]genetic-disease-300478691.html
Follow us on
Is AI Translation Quality Really Improving? views: 1503
Unlikely Friends: Blending AI and Human Interpretation to Unlock Limitless Growth views: 1488
No Experience Required: EU Hiring Translators for Eight Official Languages views: 1479